Table 3 Calculated values for the Combination Index as a growth inhibitory effect of combination treatment with Herceptin® and Cisplatin in gastric cancer cell lines
YBC-2 | Combination Index Value | Parameter (μM) | ||||
|---|---|---|---|---|---|---|
Drug | ED50 | ED75 | ED90 | Dm | m | r |
CDDP | Â | Â | Â | 4.512 | 0.921 | 0.882 |
HER | Â | Â | Â | 1201.0 | 0.316 | 0.915 |
CDDP + HER | 1.375 | 2.707 | 5.337 | 2.232 | 0.587 | 0.965 |
Diagnosis combined effect | antagonism | antagonism | antagonism | Â | Â | Â |
YBC-3 | Combination Index Value | Parameter (μM) | ||||
Drug | ED50 | ED75 | ED90 | Dm | m | r |
CDDP | Â | Â | Â | 30.733 | 2.227 | 0.929 |
HER | Â | Â | Â | 46.063 | 0.623 | 0.970 |
CDDP + HER | 0.274 | 0.110 | 0.054 | 12.091 | 1.472 | 0.998 |
Diagnosis combined effect | synergy | synergy | synergy | Â | Â | Â |
NCI-N87 | Combination Index Value | Parameter (μM) | ||||
Drug | ED50 | ED75 | ED90 | Dm | m | r |
CDDP | Â | Â | Â | 45.86 | 0.53 | 0.93 |
HER |  |  |  | 1.13E + 05 | 0.19 | 0.63 |
CDDP + HER | 0.03 | 0.01 | 0.01 | 0.83 | 0.88 | 0.96 |
Diagnosis combined effect | synergy | synergy | synergy | Â | Â | Â |
U-87 MG | Combination Index Value | Parameter (μM) | ||||
Drug | ED50 | ED75 | ED90 | Dm | m | r |
CDDP | Â | Â | Â | 5.65 | 1.08 | 0.98 |
HER | Â | Â | Â | 1845.53 | 0.46 | 0.86 |
CDDP + HER | 9.18 | 9.85 | 10.58 | 2.56 | 1.01 | 0.99 |
Diagnosis combined effect | antagonism | antagonism | antagonism | Â | Â | Â |
SK-BR-3 | Combination Index Value | Parameter (μM) | ||||
Drug | ED50 | ED75 | ED90 | Dm | m | r |
CDDP | Â | Â | Â | 20.63 | 2.42 | 0.94 |
HER |  |  |  | 1.42E + 06 | 0.05 | 0.43 |
CDDP + HER | 0 | 0 | 0 | 1.45 | 1.44 | 0.99 |
Diagnosis combined effect | synergy | synergy | synergy | Â | Â | Â |